Author:
Veltri Giuseppe Alessandro,Steinert Janina Isabel,Sternberg Henrike,Galizzi Matteo M.,Fasolo Barbara,Kourtidis Ploutarchos,Büthe Tim,Gaskell George
Abstract
AbstractWe conduct a large (N = 6567) online experiment to measure the features of non-pharmaceutical interventions (NPIs) that citizens of six European countries perceive to lower the risk of transmission of SARS-Cov-2 the most. We collected data in Bulgaria (n = 1069), France (n = 1108), Poland (n = 1104), Italy (n = 1087), Spain (n = 1102) and Sweden (n = 1097). Based on the features of the most widely adopted public health guidelines to reduce SARS-Cov-2 transmission (mask wearing vs not, outdoor vs indoor contact, short vs 90 min meetings, few vs many people present, and physical distancing of 1 or 2 m), we conducted a discrete choice experiment (DCE) to estimate the public’s perceived risk of SARS-CoV-2 transmission in scenarios that presented mutually exclusive constellations of these features. Our findings indicate that participants’ perception of transmission risk was most influenced by the NPI attributes of mask-wearing and outdoor meetings and the least by NPI attributes that focus on physical distancing, meeting duration, and meeting size. Differentiating by country, gender, age, cognitive style (reflective or intuitive), and perceived freight of COVID-19 moreover allowed us to identify important differences between subgroups. Our findings highlight the importance of improving health policy communication and citizens’ health literacy about the design of NPIs and the transmission risk of SARS-Cov-2 and potentially future viruses.
Funder
HORIZON EUROPE Framework Programme
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (2023).
2. UK Health Security Agency. Effectiveness of Non-pharmaceutical Interventions to Reduce Transmission of COVID-19 in the UK: A Rapid Mapping Review. https://assets.publishing.service.gov.uk/media/65144556b1bad400144fd910/NPI_and_COVID_mapping_review.pdf (2023).
3. Centers for Disease Control and Prevention. Benefits of Getting a COVID-19 Vaccine. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html (2023).
4. MacIntyre, C. R., Costantino, V. & Trent, M. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. Vaccine 40(17), 2506–2513 (2022).
5. Dhawan, M. et al. Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Hum. Vaccin. Immunother. 18(5), 883. https://doi.org/10.1080/21645515.2022.2068883 (2022).